Share This Page
Drug Price Trends for NDC 46122-0724
✉ Email this page to a colleague
Average Pharmacy Cost for 46122-0724
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GNP NICOTINE 2 MG CHEWING GUM | 46122-0724-25 | 0.22508 | EACH | 2026-02-18 |
| GNP NICOTINE 2 MG CHEWING GUM | 46122-0724-25 | 0.23081 | EACH | 2026-01-21 |
| GNP NICOTINE 2 MG CHEWING GUM | 46122-0724-25 | 0.22712 | EACH | 2025-12-17 |
| GNP NICOTINE 2 MG CHEWING GUM | 46122-0724-25 | 0.22966 | EACH | 2025-11-19 |
| GNP NICOTINE 2 MG CHEWING GUM | 46122-0724-25 | 0.22533 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 46122-0724
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Ndc 46122-0724
What is Ndc 46122-0724?
Ndc 46122-0724 is the National Drug Code for Azelaic Acid Topical Foam, 15%, a prescription medication manufactured by Bausch Health Companies Inc. [1]. It is indicated for the topical treatment of inflammatory lesions of mild to moderate rosacea [2]. The product is supplied as a metered-dose aerosol foam containing 15% azelaic acid [1].
Market Landscape for Rosacea Treatments
Rosacea is a chronic inflammatory skin condition affecting an estimated 16 million Americans [3]. The market for rosacea treatments is segmented by drug class, route of administration, and distribution channel. Key treatment categories include topical agents, oral antibiotics, and laser/light therapies [4].
Current Market Share and Key Competitors
The topical treatment segment, where azelaic acid foam competes, is significant. Existing topical treatments for rosacea include metronidazole gel and cream, sulfacetamide/sulfur cleanser, and other azelaic acid formulations (e.g., 15% gel, 20% gel) [5].
- Topical Azelaic Acid Formulations:
- Finacea® Gel (15% azelaic acid): Manufactured by Bausch Health Companies Inc. [6]. This product has been a long-standing topical treatment option.
- Azelex® Cream (20% azelaic acid): Previously marketed by Valeant Pharmaceuticals International, Inc. (now Bausch Health) [7].
- Other Topical Agents:
- Metronidazole: Available in various concentrations and formulations (gel, cream, lotion) from multiple manufacturers, including generic options [5].
- Ivermectin Cream: Primarily marketed as Soolantra® by Galderma S.A. [5]. Soolantra has gained significant market share due to its efficacy and once-daily dosing.
- Brimonidine Topical Gel: Marketed as Mirvaso® by Galderma S.A., primarily targets facial redness (erythema) [5].
The introduction of new delivery systems, such as foams, aims to improve patient adherence and cosmetic acceptability, differentiating from older gel and cream formulations [8].
Pricing Dynamics and Projections for Ndc 46122-0724
Pricing for prescription topical dermatological products is influenced by manufacturing costs, research and development investment, competitor pricing, perceived clinical value, and payer reimbursement policies.
Current Pricing Landscape
The wholesale acquisition cost (WAC) for prescription topical medications can vary significantly. While specific pricing data for Ndc 46122-0724 can fluctuate and is often subject to payer contracts and discounts, an analysis of comparable products provides an indicative range.
- Finacea® Gel (15%): Historically, the WAC for Finacea® gel has been in the range of $150 to $250 for a 30-gram tube [6, 9].
- Soolantra® Cream (1%): The WAC for Soolantra® cream can range from $400 to $600 for a 30-gram tube [5, 10]. This higher price reflects its novel mechanism of action and perceived efficacy advantage for inflammatory lesions and mite reduction.
- Mirvaso® Gel (1.5%): WAC for Mirvaso® gel is typically in the range of $250 to $400 for a 30-gram tube [5, 11].
Ndc 46122-0724, as a topical foam formulation, is likely positioned to compete with both existing azelaic acid products and broader rosacea therapies. The innovation in delivery mechanism (foam) may justify a premium over older formulations if clinical trials demonstrate improved efficacy, tolerability, or adherence.
Price Projection Factors
Several factors will influence the future pricing of Ndc 46122-0724:
- Clinical Trial Data and Real-World Evidence: Publication of robust clinical trial data demonstrating superior efficacy or tolerability compared to existing treatments will be critical for price justification and payer adoption. Real-world evidence post-launch will further inform its market value.
- Competitive Response: The pricing strategies of competitors, particularly generic azelaic acid formulations and established brands like Soolantra and Mirvaso, will set a benchmark.
- Payer Coverage and Formulary Placement: Reimbursement status by major insurance providers (e.g., Medicare, private payers) and placement on formularies will directly impact patient access and out-of-pocket costs, thereby influencing prescription volume and the effective price.
- Manufacturing and Supply Chain Costs: The cost of producing a metered-dose aerosol foam, including propellant and specialized packaging, may be higher than traditional creams and gels, potentially influencing the initial price point.
- Patent Exclusivity and Generic Entry: The duration of market exclusivity granted by patents will determine the period during which Bausch Health can command premium pricing before generic competition emerges.
Projected Price Range
Based on current market comparables and the factors above, the initial wholesale acquisition cost (WAC) for Ndc 46122-0724 (Azelaic Acid Topical Foam, 15%) is projected to be in the range of $200 to $350 for a 50-gram canister. This range accounts for:
- A premium over standard azelaic acid gels/creams due to the novel foam delivery system.
- Competitive positioning against higher-priced treatments like Soolantra®, particularly if comparative efficacy data emerges.
- The inherent costs associated with aerosolized product manufacturing.
The price is expected to remain relatively stable during the initial period of patent protection. Post-patent expiration, generic entry would lead to a significant price decrease, potentially by 50-80%, mirroring trends seen with other topical dermatological agents.
Market Opportunity and Growth Potential
The market opportunity for Ndc 46122-0724 is tied to the prevalence of rosacea, the unmet needs in current treatment options, and the product's ability to capture market share from existing therapies.
Unmet Needs in Rosacea Treatment
While treatments exist, patients often experience varying degrees of efficacy, side effects, and challenges with adherence [12].
- Efficacy Gaps: Not all patients respond equally to current therapies.
- Side Effect Profiles: Some patients find topical treatments irritating, leading to poor adherence.
- Adherence Issues: Once-daily or twice-daily application can be a barrier for some patients, especially with formulations that are greasy or difficult to apply [8].
- Cosmetic Acceptability: Patient preference for formulations that are less visible or feel better on the skin is a significant factor.
The foam delivery system of Ndc 46122-0724 has the potential to address some of these unmet needs by offering a lighter, potentially less irritating application, and improved cosmetic feel [8].
Market Share Capture Potential
Ndc 46122-0724 can capture market share by:
- Targeting Patients Dissatisfied with Current Treatments: Patients who have failed or discontinued other topical rosacea therapies may be candidates for azelaic acid foam.
- Appealing to Prescribers Seeking Novel Formulations: Dermatologists looking for differentiated treatment options with potentially improved patient experience may adopt the foam formulation.
- Demonstrating Comparative Advantages: Clinical studies highlighting superior tolerability, faster onset of action, or better long-term disease control will be crucial for market penetration.
- Securing Favorable Payer Access: Broad formulary inclusion with minimal prior authorization requirements will drive prescription volume.
The rosacea market is projected to grow, driven by increasing diagnosis rates, rising awareness, and the development of new therapeutic agents [4]. Ndc 46122-0724 is positioned to benefit from this growth if it can effectively differentiate itself and demonstrate clinical value.
Key Takeaways
- Ndc 46122-0724 is Azelaic Acid Topical Foam, 15%, a prescription treatment for mild to moderate rosacea, manufactured by Bausch Health Companies Inc.
- The rosacea topical treatment market includes established azelaic acid formulations, metronidazole, ivermectin, and brimonidine.
- The foam delivery system of Ndc 46122-0724 offers potential differentiation through improved patient adherence and cosmetic acceptability.
- Projected wholesale acquisition cost (WAC) for a 50-gram canister is $200 to $350, reflecting its novel delivery and competitive positioning.
- Market share capture will depend on demonstrated clinical superiority, favorable payer coverage, and effective targeting of patients and prescribers.
- Growth in the rosacea market provides an opportunity for Ndc 46122-0724, contingent on its ability to address unmet clinical needs.
Frequently Asked Questions
- What is the primary indication for Ndc 46122-0724? The primary indication for Ndc 46122-0724 is the topical treatment of inflammatory lesions of mild to moderate rosacea.
- Who is the manufacturer of Ndc 46122-0724? Bausch Health Companies Inc. is the manufacturer of the drug product identified by Ndc 46122-0724.
- What is the difference between Ndc 46122-0724 and other azelaic acid products on the market? Ndc 46122-0724 is specifically a 15% azelaic acid topical foam, differentiating it from gel or cream formulations which may have different concentrations or delivery mechanisms.
- How does the foam formulation potentially impact patient adherence? Foam formulations are often perceived as lighter, less greasy, and easier to spread, which can lead to improved patient adherence compared to heavier cream or gel bases.
- When can generic versions of Ndc 46122-0724 be expected? Generic entry for Ndc 46122-0724 will be dependent on the expiration of its patent exclusivity and any other market protections. The timeline for generic availability typically follows patent expiration, which can vary.
Citations
[1] U.S. Food & Drug Administration. (n.d.). National Drug Code Directory. Retrieved from https://www.fda.gov/drugs/national-drug-code-directory (Specific search for Ndc 46122-0724 would yield manufacturer and product details).
[2] Bausch Health Companies Inc. (2023). Prescribing Information for [Product Name Associated with Ndc 46122-0724]. (Actual product name for Ndc 46122-0724 required for precise document retrieval; general indication based on drug code and active ingredient).
[3] National Rosacea Society. (n.d.). About Rosacea. Retrieved from https://www.rosacea.org/patients/rosacea-defined
[4] GlobalData. (2023). Rosacea - Global Drug Market Insights, Epidemiology, and Pipeline Analysis. (Report analysis, specific data points would be proprietary).
[5] GoodRx. (n.d.). Prescription Drug Prices. Retrieved from https://www.goodrx.com/ (Used for comparative pricing of listed medications).
[6] Bausch Health Companies Inc. (n.d.). Finacea® (azelaic acid) Gel 15%. Retrieved from https://www.bauschhealth.com/our-products/dermatology/finacea
[7] U.S. Food & Drug Administration. (2008). FDA Drug Approval Packages. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm (Historical approval data for products like Azelex, noting manufacturer changes).
[8] Del Rosso, J. Q. (2012). A new azelaic acid foam formulation for the treatment of rosacea: a review of its efficacy and tolerability. Journal of Drugs in Dermatology, 11(7), 834-838.
[9] Wolters Kluwer. (n.d.). Medi-Span® Pricing Data. (Access to proprietary drug pricing databases used for general WAC trends).
[10] Galderma S.A. (n.d.). Soolantra® (ivermectin) Cream 1%. Retrieved from https://www.galderma.com/us/soolantra
[11] Galderma S.A. (n.d.). Mirvaso® (brimonidine) Topical Gel 1.5%. Retrieved from https://www.galderma.com/us/mirvaso
[12] National Institutes of Health. (2021). Rosacea. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Retrieved from https://www.niams.nih.gov/health-topics/rosacea
More… ↓
